Which approach fits your defect — and why that question matters first

The question most patients bring to a first consultation — 'which treatment is right for me?' — is not, in the end, a matter of preference. It is answered by three or four objective clinical findings that a good-quality knee MRI and a structured assessment can establish well before any treatment discussion begins.

Both MACI and the ChondroFiller injection target the same underlying problem: a focal articular cartilage defect in a knee that is otherwise mechanically stable. Neither is appropriate where cartilage loss is diffuse or bone-on-bone end-stage osteoarthritis is present; those presentations sit on a different pathway.

Within that shared starting point, the principal branching criteria are defect size (measured and graded on MRI using the ICRS classification), whether the patient has previously had cartilage surgery on the same knee, surgical candidacy — encompassing age, BMI, and relevant comorbidities — and the capacity to commit to a prolonged rehabilitation.

MACI is structured around larger focal defects, typically at or above 2–3 cm², in patients who can tolerate two separate surgical procedures and a recovery period of twelve to eighteen months. Several circumstances can remove MACI from the table entirely: a defect smaller than 2 cm², any prior cartilage surgery on the same knee, more than minimal osteoarthritic change, or insufficient rehabilitation capacity.

The ChondroFiller injection carries none of those structural exclusions. It suits smaller or moderate focal defects and patients for whom surgery is not appropriate or not wanted — including those whose prior cartilage procedures would disqualify them from NHS-funded MACI under NICE TA477. The precise indication for each remains a clinical determination: defect size, ICRS grade, alignment, and the patient's overall health picture all feed into it.

How MACI works: a two-stage surgical procedure

MACI unfolds in two separate procedures, typically three to six months apart. At the first, a small arthroscopic biopsy extracts a sample of healthy cartilage from a low-load area of the knee. The harvested chondrocytes are sent to a specialist laboratory where they are cultured and seeded onto a porcine Type I/III collagen membrane over four to six weeks. At the second procedure — open or arthroscopic depending on the defect's location — the surgeon prepares the lesion bed, sizes the membrane to fit, and secures it in place.

NHS access is governed by NICE Technology Appraisal TA477 (2017), which sets four simultaneous eligibility gates as described above. In practice, the gate that surprises patients most is prior surgery: a patient who has previously had any cartilage procedure on the same knee — microfracture, chondroplasty, or an earlier ACI attempt — is excluded from NHS funding even if their current defect is large and well-defined. All four criteria must be met at the same time; satisfying three is not sufficient.

Privately, MACI is typically offered to patients under 55 who are in good general health and can commit to an extended recovery. UK private costs run to approximately £30,000 or more, reflecting the two operative episodes, laboratory cell culture, and the specialist centre infrastructure required.

Rehabilitation after implantation is protracted. Partial weight-bearing restrictions are standard in the early weeks, and a structured physiotherapy programme typically spans twelve to eighteen months before return to higher-demand activity is considered. That commitment is itself a selection criterion: patients unable to follow a supervised rehabilitation plan are unlikely to be offered MACI regardless of their defect profile.

How ChondroFiller injection works: outpatient, no cell culture

Unlike MACI, ChondroFiller injection requires no biopsy, no laboratory, and no operating theatre. The procedure takes place in an outpatient setting: the treating clinician positions the needle under real-time ultrasound guidance, then delivers ChondroFiller as a liquid directly into the focal cartilage defect. Within three to five minutes of injection, the collagen hydrogel polymerises in situ, forming a dimensionally stable scaffold that conforms to the defect contour and bonds to the surrounding cartilage surface.

The product is entirely acellular — it carries no donor cells and requires none of the patient's own. Its role is mechanical and biological: to create a physical lattice from which the body's resident progenitor cells, migrating in from the surrounding synovium and subchondral bone, can populate the scaffold and progressively deposit new cartilage-like matrix. This process — acellular matrix-induced chondrogenesis — unfolds gradually over six to twenty-four months rather than at the moment of injection.

Ultrasound guidance is not incidental. Studies suggest that up to 30% of unguided joint injections fail to place material precisely within a small focal defect, making real-time image guidance clinically important to ChondroFiller accuracy rather than simply a convenience.

The eligibility structure reflects a different treatment philosophy. ChondroFiller injection carries no minimum defect size threshold, no upper age limit, and no restriction based on prior cartilage procedures — including cases where previous surgery on the same knee would disqualify a patient from NHS-funded MACI under TA477. This broader access profile means it can be considered for patients at an earlier or more moderate stage of defect progression, as well as those whose clinical history places surgical options out of reach.

What the evidence shows — and where the gaps are

The evidence base for the two treatments sits at very different points of maturity.

MACI: decade-long follow-up data

The SUMMIT randomised controlled trial established that MACI produces significantly better KOOS pain and function scores than microfracture at both 2 and 5 years for defects measuring 3 cm² or larger — a result that placed it at the head of the evidence hierarchy for larger focal lesions. A 2024 systematic review tracking 168 MACI patients (mean age 37) from implantation to a minimum of ten years found that patient-reported outcome improvements remained durable, defect fill on MRI was satisfactory in the majority of cases, the all-cause reoperation rate was 9%, and only 7.4% had progressed to total knee replacement by 10–17 years. Separately, a prospective series of 82 patients who underwent patellofemoral MACI showed sustained improvements in KOOS, SF-36, and VAS pain scores at 10 or more years, with equivalent outcomes across patellar and trochlear graft sites.

ChondroFiller injection: early signals, shorter follow-up

Published knee-specific data for ChondroFiller injection are earlier in development. The primary clinical study followed 17 patients for 12 months and found statistically significant improvements in both Lysholm and IKDC scores at 3, 6, and 12 months post-procedure, with functional gains appearing to plateau between the 6- and 12-month assessments. A 2025 prospective controlled trial is investigating ChondroFiller combined with a blood-derived stem cell-rich graft in Grade IV knee osteoarthritis — an emerging combinatorial application, though one that sits outside standard focal-defect use and should be read as hypothesis-generating rather than practice-defining.

No head-to-head trial comparing ChondroFiller injection with MACI for equivalent defects currently exists in the published literature. The practical implication is that the two treatments are not yet directly comparable on outcome data; the choice between them rests primarily on defect characteristics, eligibility, and procedural factors rather than on matched clinical results.

Practical differences: cost, access, recovery, and waiting times

For many patients, the practical differences between these two pathways are as consequential as the clinical ones.

Access and waiting times

MACI carries a commissioned NHS pathway, but navigating it takes time. Passing all four TA477 eligibility gates and obtaining referral to a designated tertiary centre introduces cumulative delays — across the initial referral, biopsy scheduling, the laboratory culture period, and the implantation surgery itself. Patients who fall outside the NHS criteria must self-fund privately.

ChondroFiller injection has no NHS commissioning route. As a private outpatient procedure, it does not require a GP referral and is not subject to NHS-style waiting times. Lincolnshire Knee, part of the MSK Doctors group, accepts patients on this basis and can offer assessment without the multi-stage referral process MACI requires.

Cost

The cost difference is substantial. ChondroFiller injection is priced at approximately £3,000–£9,800 privately, depending on defect size and clinic — a fraction of what MACI requires when self-funded. For patients who fall outside NHS eligibility, this contrast may be a defining practical factor.

Recovery

The two recovery pathways differ in structure as much as in duration. MACI imposes a mandatory gap between its two surgical stages, followed by protected weight-bearing and a rehabilitation programme that extends well into — and often beyond — the first post-operative year before return to strenuous activity.

ChondroFiller injection is completed in a single outpatient visit with same-day discharge, and return to daily activity typically progresses over weeks to months. That shorter procedural footprint should not be read as an absence of recovery. The scaffold-supported chondrogenesis is a gradual biological process: published data suggest functional improvements accumulate through the first 12 months, with gains often plateauing between the six- and twelve-month assessments. Full symptomatic benefit may not be apparent until the 12-month mark, and progressive rehabilitation remains part of the pathway throughout.

Getting the right assessment for a focal cartilage defect

Treatment selection between these two pathways is not a conversation that can happen without detailed imaging. The starting point is always MRI — specifically, a scan that characterises the defect by size, depth, ICRS grade, and subchondral bone involvement. Those measurements, rather than symptom severity alone, determine which options are technically appropriate and, in the case of MACI, whether NHS eligibility criteria are met at all.

At Lincolnshire Knee's Sleaford site, onMRI™ AI-assisted knee MRI analysis supports cartilage and meniscus segmentation alongside T2 mapping, providing the structural granularity — including defect depth and early subchondral change — that guides these pathway decisions.

Joint alignment is a variable clinicians assess alongside cartilage characterisation. A varus or valgus malalignment concentrating load through the damaged compartment can compromise any repair over time, regardless of which technique is used. Where malalignment is identified, an osteotomy — such as a high tibial osteotomy (HTO) or distal femoral osteotomy (DFO) — may be considered alongside or prior to the cartilage procedure.

When imaging confirms a defect profile suited to MACI, the two-stage surgical pathway and its funding route can be discussed in full. Where the profile, surgical risk, or recovery capacity makes that pathway unsuitable, ChondroFiller injection should be discussed explicitly as a clinically substantiated option with its own evidence base — not as a fallback, but as a distinct therapeutic choice.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral. Book an assessment at lincolnshireknee.co.uk.

1. [1] Prospective Clinical and Radiological Follow-Up Beyond 10 Years in Patients Undergoing MACI in the Patellofemoral Joint. (2024). https://doi.org/10.1177/2325967124s00196 https://doi.org/10.1177/2325967124s00196
2. [2] Implantation of ChondroFiller Liquid® as a Scaffold Material for the Treatment of Chondral Lesions of the Knee Joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
3. [3] Minimum 10-Year Outcomes of Matrix-Induced Autologous Chondrocyte Implantation in the Knee. (2024). https://doi.org/10.1177/03635465231205309 https://doi.org/10.1177/03635465231205309
4. [4] Joint Preservation in Patients with Grade IV Osteoarthritis of the Knee: Acellular Collagen Scaffold (ChondroFiller® Liquid) and Blood Derived Stem Cell Rich Graft — Prospective Controlled Trial. (2025). https://doi.org/10.29011/2575-9760.011360 https://doi.org/10.29011/2575-9760.011360
5. [5] Comparison of Three Techniques for Cartilage Lesions: MACI vs AMIC and Arthroscopic Minced Cartilage — 2-Year Follow-Up. (2025). https://doi.org/10.3390/jcm14072194 https://doi.org/10.3390/jcm14072194